<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932724</url>
  </required_header>
  <id_info>
    <org_study_id>CY503C2</org_study_id>
    <secondary_id>EudraCT no. 2008-005536-32</secondary_id>
    <nct_id>NCT00932724</nct_id>
  </id_info>
  <brief_title>CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer</brief_title>
  <acronym>CY503C2</acronym>
  <official_title>Phase II Double-blind Placebo-controlled Trial of CY503 in Patients With Chemotherapy-refractory Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytavis Biopharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cytavis Biopharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed as a phase II evaluation of the effect of CY-503 or placebo on&#xD;
      progression free survival (PFS) defined as the time from start of treatment until the&#xD;
      objective observation of progressive disease (PD) or death from any course in patients with&#xD;
      chemotherapy-refractory metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer has a worldwide annual incidence of approximately 1 million new cases&#xD;
      diagnosed yearly and it is the second leading cause of cancer-related death in Western&#xD;
      nations. There are a couple of approved standard therapies for the treatment of MCRC with&#xD;
      cytotoxic agents irinotecan, oxaliplatin, and the fluoropyrimidines , as well as bevacizumab,&#xD;
      the antibody against vascular endothelial growth factor A, and cetuximab, the antibody&#xD;
      against the epidermal growth factor receptor. But there are only a few studies achieving a&#xD;
      median survival time of more than 20 months in MCRC patients with standard regimens. After a&#xD;
      1st line therapy a high proportion (50% to 80%) of patients receives a 2nd line therapy with&#xD;
      drugs not used in 1st line therapy and a part of them gets a 3rd line treatment. Results from&#xD;
      a 2nd line therapy are best response rates ranging from 4 % - 23 %, a median PFS rate of 5.1&#xD;
      months, a median TTP of 4.1 - 4.6 months and median overall survival 6.9 - 12 months.&#xD;
      However, for patients who experience disease progression after standard therapy (definition&#xD;
      see inclusion criteria) there is no further standard therapeutic option. These patients&#xD;
      developed a resistance to these therapies and finally die of their disease. They generally&#xD;
      get best supportive care (BSC). Thus, there is a need for new active treatment options in&#xD;
      this setting.&#xD;
&#xD;
      In this phase II double-blind placebo-controlled trial the efficacy and safety of CY-503, 350&#xD;
      ng s.c. injected in patients with chemotherapy refractory MCRC are tested. Approved&#xD;
      treatments given to MCRC patients are usually discontinued after a treatment over some weeks&#xD;
      at the first detection of objective PD. It will be tested if CY-503 is able to achieve&#xD;
      progression-free-survival (PFS) in comparison to placebo. Patients will initially be included&#xD;
      to receive either CY-503 or placebo until documentation of objective PD.&#xD;
&#xD;
      Standard therapy must be finished and has shown objective PD. Also patients with&#xD;
      contraindications to standard therapy can be included.&#xD;
&#xD;
      CY-503 shows the potential to improve treatment of MCRC. This study aims at evaluating the&#xD;
      activity and therapeutic effects of the substance. Anticipated capabilities are substitution&#xD;
      of cytostatic drugs or improvement of their efficacy and tolerability . Furthermore, the&#xD;
      expected improvement of PFS rates after failure of standard chemotherapies has to be&#xD;
      investigated.&#xD;
&#xD;
      In a phase I trial CY-503 showed SD in patients who had exhausted standard therapy options&#xD;
      for metastatic disease with subsequent disease progression with a median TTP of 17.4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The sponsor declared the early termination of the study due to poor recruitment of patients.&#xD;
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor assessment by using CT scans and/or MRIs</measure>
    <time_frame>every 8 weeks (each 2 cycles)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events</measure>
    <time_frame>every 4 weeks (every cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life using a standardized questionaire</measure>
    <time_frame>every 4 weeks (every cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of survival by &quot;physical exam&quot;</measure>
    <time_frame>every 4 weeks (every cycle) / every 3 months during follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>CY-503</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CY-503</intervention_name>
    <description>Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks</description>
    <arm_group_label>CY-503</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patients are eligible with diagnosis of measurable metastatic colorectal carcinoma and&#xD;
             radiologic documentation of disease progression during or with 3 months after&#xD;
             termination of standard chemotherapy (fluoropyrimidine-based therapy with oxaliplatin&#xD;
             and irinotecan). Patients who had to interrupt the 1st or 1nd line therapy due to&#xD;
             intolerance or who were refractory or intolerant to the standard treatment regimens&#xD;
             are eligible, too. Bevacizumab can, but does not need to be administered at discretion&#xD;
             of treating physician. Patients with K-RAS wild-type can be treated with cetuximab or&#xD;
             panitumumab before they enter the study.&#xD;
&#xD;
          -  No chemotherapy within 4 weeks before treatment start&#xD;
&#xD;
          -  No residual significant toxicity (greater than NCI grade 1), in case of peripheral&#xD;
             neuropathy: no symptoms of peripheral neuropathy of NCI CTC grade 4 within 4 weeks&#xD;
             before treatment start.&#xD;
&#xD;
          -  No previous treatment with experimental therapies after standard therapies is allowed.&#xD;
&#xD;
          -  Patients must use effective contraception if of reproductive potential. Females must&#xD;
             not be pregnant or lactating&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance status of 0 - 2&#xD;
&#xD;
          -  WBC ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3, platelet count&#xD;
             ≥100,000/mm3&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL (40 μmol/L) (unless due to Gilbert's syndrome in which case the&#xD;
             bilirubin should be ≤3.5 mg/dL (59.86 μmol/L)), aspartate transaminase (AST)/alanine&#xD;
             transaminase (ALT) ≤ 5 × upper limit of normal (ULN); hepatic alkaline phosphatase ≤&#xD;
             3.0 × ULN (in case of liver metastases higher levels do not hinder inclusion of&#xD;
             patients)&#xD;
&#xD;
          -  Serum creatinine ≤ 2.0 mg/dL (180 μmol/L)or creatinine clearance &gt;= 50 ml/min. ,&#xD;
             proteinuria &lt; 2.0 g/24 hr urine collection in patients with a positive urine dipstick&#xD;
             for protein&#xD;
&#xD;
          -  Written informed consent according to ICH-GCP and national laws and regulations prior&#xD;
             to receipt of any trial medication or beginning trial procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of any other malignant disease (with the exception of tumors operatively&#xD;
             cured at least 5 years prior to the trial)&#xD;
&#xD;
          -  Known brain metastases&#xD;
&#xD;
          -  Uncontrolled pleural effusions&#xD;
&#xD;
          -  Interstitial pneumonitis or pulmonary fibrosis&#xD;
&#xD;
          -  Severe/ unstable systemic disease or infection and circumstances not permitting trial&#xD;
             participation (e.g., alcoholism or substance abuse)&#xD;
&#xD;
          -  Unstable cardiac disease in the last 6 months&#xD;
&#xD;
          -  Use of conventional mistletoe preparations, any immunostimulating substances and/or&#xD;
             monoclonal antibodies within four weeks prior to and during the trial - ongoing&#xD;
             therapy with steroids is permitted if the dose is not higher than 20 mg of&#xD;
             prednisone-equivalent at the time of inclusion and during this clinical trial&#xD;
&#xD;
          -  Any evidence or history (elicited by the investigator) of symptomatic cerebrovascular&#xD;
             events (i.e., stroke or transient ischemic attack) within 6 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Any history or evidence of pulmonary embolism or thrombophlebitis (including deep vein&#xD;
             thrombosis) requiring anticoagulant therapy (e.g., marcumar or heparin)&#xD;
&#xD;
          -  History of hypersensitivity to mistletoe&#xD;
&#xD;
          -  History of primary immunodeficiency&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) or known active viral hepatic infections&#xD;
&#xD;
          -  Prior treatment with CY-503&#xD;
&#xD;
          -  A general medical or psychological condition or behaviour, including substance&#xD;
             dependence or abuse that, in the opinion of the investigator, might not permit the&#xD;
             patient to complete the trial or sign the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz Zwierzina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Innsbruck, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lothar Bergmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bezirkskrankenhaus Hall</name>
      <address>
        <city>Hall in Tirol</city>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bezirkskrankenhaus Kufstein</name>
      <address>
        <city>Kufstein</city>
        <zip>6330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vinzenz Krankenhaus Zams</name>
      <address>
        <city>Zams</city>
        <zip>6511</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Altenburger Land GmbH</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesundheitszentrum St. Marien GmbH am Klinikum St. Marien</name>
      <address>
        <city>Amberg</city>
        <zip>922224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum f. Hämatologie, Onkologie u. Diabetologie</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund GmbH</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westdeutsches Tumorzentrum - Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>7370</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang-Universität Frankfurt</name>
      <address>
        <city>Frankfurt a.M.</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther Universität Halle</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinkum Heidelberg - Nationales Centrum f. Tumorerkrankungen</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Herne</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Hildesheim</city>
        <zip>31135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Hof</city>
        <zip>95028</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie und internistische Onkologie</name>
      <address>
        <city>Kronach</city>
        <zip>96317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Onkologie</name>
      <address>
        <city>Köln</city>
        <zip>51103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lüdenscheid</name>
      <address>
        <city>Luedenscheid</city>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg gGmbH</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanness-Gutenberg Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie und internistische Onkologie</name>
      <address>
        <city>München</city>
        <zip>80638</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis f. Hämatologie u. Onkologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosper-Hospital</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis, Hämatologie und Onkologie</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nordoberpfalz AG</name>
      <address>
        <city>Weiden Oberpfalz</city>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>July 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2009</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <responsible_party>
    <name_title>Prof. Hans Lentzen, PhD</name_title>
    <organization>Cytavis Biopharma GmbH</organization>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Colorectal</keyword>
  <keyword>Cancer</keyword>
  <keyword>refractory</keyword>
  <keyword>Phase II</keyword>
  <keyword>randomised</keyword>
  <keyword>double-blind</keyword>
  <keyword>controlled</keyword>
  <keyword>multicenter</keyword>
  <keyword>CY-503</keyword>
  <keyword>Cytavis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

